US FDA approves use of Sanofi's meningococcal vaccine in infants
French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group.
The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria - A, C, W and Y, the company said on 23 May 2025.
Meningococcal infections, caused by the Neisseria meningitidis bacteria, can cause serious, sometimes deadly, bloodstream infections, as well as severe swelling in the brain and spinal cord. British drugmaker GSK's shot Menveo is approved in children as young as two months and adults up to 55 years of age.
"I think for convenience factor and accessibility... it is nice to have options," said Patty Sabey, a paediatrician with Stanford Medicine Children's Health, ahead of the decision.
The approval was based on data from three late-stage studies involving more than 6,000 participants aged six weeks to 19 months, which showed that MenQuadfi was as effective as Menveo when co-administered with other routine paediatric vaccines.
Sabey said meningococcal vaccine is not a routine vaccine for infants in the U.S. even though young infants, especially under one year, are at higher risk of infection.
The U.S. Centers for Disease Control and Prevention currently recommends all adolescents aged 11 to 12 years should receive a meningococcal vaccine, followed by a booster dose at age 16 years. The agency also recommends that individuals aged two months and older who are at increased risk of the disease should receive the vaccine.
According to preliminary data from the CDC, 503 confirmed and probable cases of meningococcal disease were reported last year, the highest since 2013.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Ireland probes mistreatment at care homes run by French company
Representative AI image DUBLIN: Ireland's health ministry Thursday ordered a probe into French care homes operator Emeis, the country's biggest private nursing home provider, after a television programme alleged residents in two places were mistreated. The investigative programme aired undercover footage of elderly residents allegedly forced into chairs, and being ignored when they pleaded for help to go to the toilet. The programme, shown on Irish state broadcaster RTE on Wednesday, also showed some residents were left in incontinence pads for so long their clothes were soaked. The scenes were "extremely distressing" and "wholly unacceptable", health ministry official Kieran O'Donnell told RTE Thursday. The ministry has ordered the Health Information and Quality Authority (HIQA) to launch a review of all nursing homes operated by Emeis, he said. Offering its "sincere apologies", the firm said "this is not the standard of care it expects and not what residents and their families deserve", and pledged to review all operations across Ireland. Emeis, which was called Orpea until last year, run 27 private nursing homes in Ireland. The company entered the Irish market in 2020 through the takeover of another portfolio. HIQA, who are tasked with inspecting care homes, said Emeis-run homes including the two featured in Wednesday's programme had triggered recent concerns. Earlier this year, HIQA ordered one of them to cease admitting new residents, citing "significant concerns". Minister for Enterprise Peter Burke told RTE an institution should not be operating "if people are not being cared for appropriately, with dignity, with respect". "HIQA need to really enforce that and to ensure that everyone has a basic level of dignity and care that they deserve in their twilight years," said Burke. Emeis changed its name to turn the page on a scandal in France when its homes came under scrutiny following the 2022 publication of the book "The Gravediggers" by independent journalist Victor Castan. It cited employees and relatives claiming that residents were at times left for hours with soiled underwear or went days without care as managers sought to maximise profit margins. Orpea contested those claims as "untruthful, scandalous and injurious".
News18
2 days ago
- News18
From Failed Psychiatrist To $149-Million Fraud: Indian-Origin Man's Trail Of Scandal In US
Last Updated: Tonmoy Sharma, once a high-profile doctor in the UK, has long courted headlines- first for his research work and then for the ethical and legal storms that followed. Indian-origin doctor Tonmoy Sharma was arrested in the United States for allegedly masterminding a $149-million healthcare fraud. The 58-year-old was taken into custody at Los Angeles International Airport as he was allegedly preparing to flee to Dubai. Tonmoy Sharma, once a high-profile doctor in the UK, has long courted headlines- first for his research work and then for the ethical and legal storms that followed. Tonmoy Sharma first rose to prominence in the 1990s for conducting clinical trials for major pharmaceutical companies in the UK. But his reputation began to unravel in 2001 when concerns were raised about irregularities in a £250,000 study comparing Sanofi's antipsychotic drug Amisulpride with a rival from Eli Lilly. Sanofi launched a private investigation after their medical adviser, Catherine Baxter, flagged discrepancies in Tonmoy Sharma's work. The probe uncovered a series of ethics violations which included fabricated approvals from ethics committees, recruitment of vulnerable patients without proper consent, financial incentives to encourage participation and false academic claims including a non-existent professorship and doctorate. In 2007, after multiple complaints and an investigation by the UK's General Medical Council, Tonmoy Sharma's medical licence was revoked. He was found guilty of serious professional misconduct after which he moved to the United States. Allegations In The US In California, Tonmoy Sharma established Sovereign Health Group, which rapidly grew into a prominent network of addiction treatment centres. Since 2017, Sovereign has been under investigation by the FBI for suspected fraud. In 2018, federal agents raided the group's headquarters in San Clemente, several treatment centres and Tonmoy Sharma's residence in San Juan Capistrano. Though Sovereign shut down that year, Tonmoy Sharma continued operating under a new name- Dana Shores Recovery- using a different license to stay under the radar. According to the federal indictment, Tonmoy Sharma and his associates submitted more than $149 million in fraudulent insurance claims and received at least $21 million in illegal kickbacks for patient referrals. He now faces four counts of wire fraud, one count of conspiracy, and three counts of receiving illegal remunerations. If convicted, Tonmoy Sharma could face up to 20 years in prison for each wire fraud charge, five years for conspiracy, and 10 years for each kickback-related offense. About the Author Mallika Soni Get breaking news, in-depth analysis, and expert perspectives on everything from geopolitics to diplomacy and global trends. Stay informed with the latest world news only on News18. Download the News18 App to stay updated! First Published: June 05, 2025, 20:53 IST
Business Standard
2 days ago
- Business Standard
Servier India introduces 'Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
VMPL Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication. Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40% of AML patients in India receive adequate treatment1, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced.2 The announcement marks a significant advancement in management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need. Speaking on the occasion, Mr. Aurelien Breton, Managing Director, Servier India, said, "Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most. By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch is a significant step forward in our mission to support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India." IDH1 mutation occurs in approximately 7-14% of AML patients in India3, making targeted mechanisms especially relevant for this subset. "This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.", highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India. Speaking on the importance of treatment access, Ms. Pratima Tripathi, Commercial Director, Servier India, said: "Our foremost priority is to ensure that the therapy is accessible and affordable to patients across India. We are actively collaborating with healthcare providers, patient advocacy groups, and policymakers to remove barriers and facilitate timely access to this important therapy. Through these partnerships, we are committed to expanding treatment options and making a meaningful difference in the lives of patients." By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patients. Disclaimer: This press release is intended solely to share regulatory and medical information regarding the launch; the reference to "Tibsovo" is not intended as a promotional or public advertisement. Use of the therapy is strictly based on a doctor's prescription and clinical discretion. About Servier India Servier India has been committed for over three decades to delivering innovative pharmaceutical solutions that improve the lives of patients and their families across India. Established in 1985 as an affiliate of the leading independent French pharmaceutical Servier Group, the company focuses on therapeutic areas such as Cardiometabolism, Neuroscience, Venous Diseases, and Oncology. Servier India has a strong pan-India presence and a dedicated workforce of around 580 that strives to address critical healthcare challenges with passion and purpose. As part of Servier group operating in over 150 countries, Servier India inherits a rich legacy of scientific excellence and patient-centric innovation. Globally, Servier invests heavily in research and development, focusing on our key therapeutic areas. About Servier Servier is a global pharmaceutical group governed by a Foundation that aspires to serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. As a world leader in cardiometabolism and venous diseases, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. Headquartered in France, Servier relies on a strong geographical footprint; its medicines are available in close to 140 group achieved a revenue of EUR5.9 billion in 2024. Additional Details on Ivosidenib Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea. In the United States, the US FDA approved it in 2019 as a monotherapy and later in May 2022 as a combination treatment with Azacitidine for patients aged 75 and above, or those who cannot tolerate intensive chemotherapy. The European Medical Agency (EMA) gave its approval in May 2023 for use in patients who are not fit for standard induction chemotherapy. In India, the process moved forward in April 2025, when the Subject Expert Committee (SEC) gave a positive recommendation for Ivosidenib. Following this, the DCGI granted approval for the marketing authorization in May 2025
